- CureVac N.V. (NASDAQ:CVAC +5.2%) has announced the start of an expansion of the ongoing Phase 1 study for its RNA-based cancer drug candidate, CV8102, in patients with advanced melanoma.
- With the expansion part involving 30 patients with PD-1 refractory melanoma, the company intends to confirm the safety, tolerability, and efficacy of CV8102 at 600µg, the selected dose for a Phase 2 clinical trial.
- For additional clinical insights, it will also evaluate the effects of CV8102 on systemic and intratumoral immune markers.
- 30 patients will receive intratumoral injections of CV8102 in combination with PD-1 antibodies, and ten will be treated with CV8102 only.
- For its mRNA-based vaccine candidate against COVID-19, CureVac has partnered with GlaxoSmithKline to target the emerging variants.